{
    "clinical_study": {
        "@rank": "82418", 
        "arm_group": [
            {
                "arm_group_label": "LY2835219 Standard", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of LY2835219 given with a standard meal in one of three study periods."
            }, 
            {
                "arm_group_label": "LY2835219 Fasted", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of LY2835219 given with no food in one of three periods."
            }, 
            {
                "arm_group_label": "LY2835219 High-Fat", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of LY2835219 given with a high fat meal in one of three periods."
            }
        ], 
        "brief_summary": {
            "textblock": "Participants in this study will receive 3 single oral doses of LY2835219 at least 14 days\n      apart.  One dose will be given with a standard meal, one dose with a high-fat meal and one\n      dose without food.  The study will evaluate the effects of the standard and high-fat meals\n      on how much drug gets into the bloodstream.  Side effects will be documented.  This study is\n      approximately 43 days, not including screening. Screening is required within 28 days prior\n      to the start of the study."
        }, 
        "brief_title": "A Study of LY2835219 in Healthy Participants", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy sterile males or surgically sterile or postmenopausal females\n\n          -  Have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m^2),\n             inclusive, at screening\n\n          -  Are able to eat a high-fat, high-calorie meal\n\n        Exclusion Criteria:\n\n          -  Participated in a clinical trial involving investigational product within 30 days\n\n          -  Abnormal blood pressure\n\n          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of\n             the investigator, increases the risks associated with participating in the study\n\n          -  Have donated blood of more than 500 milliliter (mL) within the last month\n\n          -  Show evidence of human immunodeficiency virus, hepatitis B or hepatitis C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059148", 
            "org_study_id": "15175", 
            "secondary_id": "I3Y-MC-JPBG"
        }, 
        "intervention": {
            "arm_group_label": [
                "LY2835219 Standard", 
                "LY2835219 Fasted", 
                "LY2835219 High-Fat"
            ], 
            "description": "Administered orally.", 
            "intervention_name": "LY2835219", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through 192 hours post dose in each period"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2835219", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through 192 hours post dose in each period"
            }, 
            {
                "measure": "Pharmacokinetics: Time of Maximum Observed Concentration (tmax) of LY2835219", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through 192 hours post dose in each period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059148"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}